By InvitationNot Applicable

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

United States1,700 participantsStarted 2026-02-15

Plain-language summary

This pragmatic clinical trial is being conducted to test the effectiveness of AI in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 4 primary care clinics. This is an autonomous AI-based screening to detect diabetic eye disease at primary care visits.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Clinic Inclusion Criteria: * Serve at least 267 patients with diabetes during the study period * No point-of-care screening system in use for diabetic eye disease * Agree to share limited identifiers data as requested Patient Inclusion Criteria: * Age 22 years or older * Diagnosis of type 1 or 2 diabetes * No known diabetic eye disease * No diabetic eye exam in the past 12 months Exclusion Criteria: * Have a documented eye exam in the electronic health record within 12 months of the date of the primary care visit. * Contraindication includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion. * Pregnant

What they're measuring

Proportion of patients who get eye screening in the AI and usual-care arms within 5 months of the recommendation

Timeframe: up to 5 months

Trial details

NCT IDNCT07559292

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02

View on ClinicalTrials.gov More Vision Disorders trials